Articles tagged with Lung Cancer
A large international trial found that sub-lobar surgery is non-inferior to lobectomy for patients with peripheral non-small cell lung cancer. The study, which enrolled 1,080 patients, showed similar disease-free survival rates between the two groups.
A randomized phase II trial demonstrated improved 18-month progression-free survival with nivolumab alone or combined with ipilimumab compared to historical controls. The combination of nivolumab and ipilimumab resulted in a higher incidence of treatment-related adverse events, but consistent with prior reports.
The IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC ≥1% stage II-IIIA population, with a clinically meaningful improvement observed across most subgroups. The study found no separation for the ITT population or all-randomized, stage II–IIIA populations.
A UK-based smoking cessation program, YESS, reported a 30% abstinence rate among patients with lung cancer who participated in a personalized support program. The study found that women achieved higher quit rates compared to men, highlighting the need for continued support.
Combining sotorasib with pembrolizumab or atezolizumab demonstrated durable clinical activity, lower treatment-related adverse events, and improved overall survival in patients with advanced KRAS p.G12C NSCLC. The study showed a higher incidence of grade 3-4 adverse events initially, but these effects may be mitigated by dose reduction.
Research presented at the IASLC World Conference on Lung Cancer 2022 found that increased utilization of Stereotactic Body Radiotherapy (SBRT) has decreased treatment disparities for early-stage non-small cell lung cancer (NSCLC). The study showed a significant increase in the proportion of patients receiving definitive treatment, with...
A phase 3 trial showed sugemalimab improved progression-free survival (PFS) by 69% compared to placebo, with a median PFS of 10.5 months. Overall survival (OS) data also suggested a trend towards benefit favoring sugemalimab.
A Phase 2 study demonstrated the accuracy of lung cancer gene panel testing using cytological specimens, with a success rate of 100% and sufficient yield for analysis. The extracted nucleic acid quality was also adequate for panel analysis, enabling the detection of gene mutations in 68.1% of cases.
The NELSON Trial demonstrated a 24% reduction in lung cancer mortality with low-dose CT screening, compared to the 20% found in the NLST. The new protocol used in NELSON showed improved sensitivity for early-stage cancers, increasing the benefits of lung cancer screening while reducing unnecessary follow-up procedures.
The IASLC Early Detection and Screening Committee report outlines the challenges of implementing lung cancer screening in low- and middle-income countries. The committee emphasizes the need for evidence-based guidelines, considering regional specificities and population-specific risk factors.
A study presented at the IASLC World Conference on Lung Cancer 2022 found four molecular subtypes of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping, each with distinct clinical characteristics and responses to treatment.
A study analyzing surgical tissue samples from patients with stage IIIA NSCLC found that high AKT expression and activated dendritic cells were associated with lower progression-free survival and overall survival. The immune expression signature identified could help follow-up and therapeutic management of high-risk patients.
A recent study found that younger patients with lung cancer are more likely to be diagnosed at later stages, highlighting the need for strategies to increase early detection among younger adults. In contrast, older patients have seen improvements in earlier stage diagnoses since the onset of lung cancer screening.
A budget impact analysis shows that implementing the NELSON screening model in 28 European countries could prevent over 18,000 premature lung cancer deaths. The model estimates a total budget impact of approximately €937 million if half of the eligible population is screened.
A new set of guidelines aims to increase patient diversity in lung cancer clinical trials by relaxing eligibility requirements. The recommendations, published in JAMA Oncology, suggest that patients with prior or concurrent cancers, brain metastases, and mild liver impairment can be included in trials.
Researchers at Cedars-Sinai Cancer identified genetic signatures linked to patient response to immunotherapy in bladder and other cancers. High DDR1 expression is associated with 'cold' tumors, while high DDR2 is linked to 'hot' tumors.
A University of Michigan-led analysis found that training patients to voice their concerns and advocate for themselves can reduce the impact of physicians' racial biases on care. The study showed that 'patient activation' creates more equitable interactions between patients and physicians.
A new study published in the Journal of Thoracic Oncology found that cytisine, a plant-based alkaloid, is a safe and effective smoking cessation therapy. The study showed a 32.1% quit rate for participants taking cytisine compared to 7.3% for those receiving a placebo.
A new study found that over half of adult cancer survivors experience significant hearing problems after chemotherapy treatment. The researchers also discovered that platinum and taxane drugs, commonly used to treat the majority of cancers, are linked to high rates of hearing loss and tinnitus.
Researchers used Guardant NGS to analyze nearly 17,000 lung cancer samples and found MET amplification in 1.2% of cases, with 20.8% having overlapping oncogenic drivers. The study suggests that high gene copy numbers and smaller amplified regions can be used to enrich for the true MET-sensitive population.
Researchers have found a promising new combination therapy that uses immunotherapy alongside a drug blocking a common gene mutation in lung cancer. The study suggests this combination may be effective in 'immune hot' tumours, which are more likely to respond.
Researchers at UC Santa Cruz discovered that a key genetic mutation in the KRAS gene alters RNA 'dark matter', leading to the release of previously unknown RNA biomarkers. These biomarkers could be detected in the blood through a liquid biopsy, offering a promising step in cancer early detection.
Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.
A national, randomized trial found that intensive telephone-based cessation counseling resulted in a two-fold greater cigarette quit rate than minimal counseling and nicotine replacement. The study also showed significant benefits for people with higher nicotine dependence and those who engaged more with the counseling.
A large-scale study analyzing 29 studies and 139,624 participants found that people who viewed tobacco content on social media are more likely to report using tobacco. The study also identified susceptible individuals who may be influenced by pro-tobacco content.
The study found an overall response rate of 32% across all patients with EGFR exon 20 mutations, varying depending on the location of the mutation. Near-loop insertions showed a 46% overall response rate, while far-loop insertions had no response rate.
Researchers discovered a new biomarker for radiation resistance in lung cancer, the PTEN mutation, and developed experimental inhibitors that can block DNA repair enzymes. This may lead to more targeted treatment approaches and improved patient outcomes.
Researchers have found that tumor cells co-exist with normal tissue in a complex, heterogeneous mixture, leading to unexpected effects on therapeutic resistance. The study suggests that understanding these ecological interactions could lead to novel treatment strategies and improved patient outcomes.
Researchers discovered that treatments aiming to suppress tumour growth while boosting the immune system may be counterproductive. The 'energy fingerprints' of lung cancer reveal that cancer cells and immune cells rely on the same energy source, glutamate.
A $5.3 million grant will support a Proteogenomic Translational Research Center analyzing lung tumors from clinical trial patients to identify biomarkers for cancer recurrence. The study aims to predict which tumors are likely to return after surgery and chemotherapy, with the goal of developing new therapeutic strategies.
Researchers will develop and test new beacon molecules and imaging equipment to improve the detection and removal of non-small-cell lung cancers, aiming to reduce unnecessary tissue removal. The goal is to enhance surgical outcomes and improve patient care.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
A systematic review of 84 studies found insufficient evidence that multivitamins or supplements can prevent cardiovascular disease and cancer in healthy adults. In contrast, diet and exercise are key to maintaining health. Whole fruits and vegetables contain a mixture of vitamins, phytochemicals, fiber, and other nutrients that act syn...
A recent study found that lower-income and less-educated patients, particularly those from racial/ethnic minorities, have a higher likelihood of being diagnosed with advanced lung cancer. The association between socioeconomic status and lung cancer stage at diagnosis was observed across different ethnicities, healthcare facilities, and...
The US Preventive Task Force's revised guidelines have increased the proportion of African Americans screened for lung cancer, a move expected to lead to more lives saved. The study, published in JAMA Network Open, analyzed data from over 800 patients and found that those eligible under the new criteria had a significantly higher rate ...
Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
A new drug combination of ramucirumab and pembrolizumab significantly extended overall survival in advanced non-small cell lung cancer patients who had progressed on prior immunotherapy. The study found a 31% reduction in risk of death compared to standard therapy, with median overall survival times of 14.5 months.
A phase 2 trial of the experimental drug adagrasib showed a 42.9% objective response rate and median overall survival of 12.6 months in patients with KRAS-mutated non-small cell lung cancer. The treatment also achieved a 33.3% response rate in patients with stable brain metastases.
A combination of ramucirumab and pembrolizumab reduced the risk of death by 31% compared to standard care in advanced non-small cell lung cancer patients who had previously failed immunotherapy. The study found that these patients lived significantly longer, with a mean overall survival time of 14.6 months.
A Phase II clinical trial found that an immunotherapy drug combination extended the lives of patients with non-small cell lung cancer, improving survival by 14.5 months compared to standard care therapy. The treatment also reduced chemotherapy use and side effects.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
A study by Cedars-Sinai researchers confirms that counting metastatic lymph nodes is a dominant predictor of cancer death, improving staging and treatment for solid tumors. The simple process can be applied in virtually all medical settings without increased cost or complexity.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
New research reveals that age-induced changes in lung fibroblasts reactivate dormant melanoma cells, promoting growth and metastasis. The study found that WNT5A signaling pathway regulates tumor cell dormancy and metastasis initiation, with increased sFRP1 secretion facilitating reactivation in the aged lung.
A recent study published in Pharmaceutics suggests that berberine can suppress the proliferation of lung cancer cells, reduce airway inflammation, and modulate genes involved in inflammation. The researchers used liquid crystalline nanoparticles to enhance safety and effectiveness.
Researchers at Penn Medicine have developed an imaging agent that detects cancer cells in real-time during biopsies, offering promise for earlier and more accurate diagnoses. The technology, known as NIR-nCLE, uses a combination of near-infrared tracers and confocal laser endomicroscopy to identify microscopic cancer cells.
According to a study published at the ATS 2022 international conference, nearly half of patients with abnormal findings in lung cancer screening experienced delays in following up. The median delay time was 91 days, with current smokers having longer delays than former smokers.
A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) found that incorporating the Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) program into electronic health records can significantly improve smoking cessation rates among cancer patients. The research demonst...
A systematic review and meta-analysis of 81 studies found that COVID-19 patients with cancer had a higher risk of death compared to those without cancer. Younger age, lung, and hematologic cancers were identified as risk factors for poor outcomes from COVID-19
A new study from McGill University finds that people living near regions prone to wildfires may have a higher incidence of lung cancer and brain tumors. Exposure to carcinogenic wildfire pollutants on a chronic basis increases the risk of certain cancers, according to researchers.
A team of researchers used a CRISPR-based approach to study the evolution of lung cancer cells, tracking their history from the first activation of cancer-causing mutations. The study revealed significant diversity between subpopulations of cells within the same tumor, with certain groups becoming more fit and aggressive over time.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
A recent study presented at the 2022 ARRS Annual Meeting found that COVID-19 infection significantly impacted lung cancer screening in diverse inner-city populations. The research revealed that approximately 9% of participants developed COVID-19 during the pandemic, with mortality rates reaching 6.9%.
Researchers developed a model using radiomic features from screening images to identify high-risk lung cancer patients. The model divided patients into groups according to their risk of having poor outcomes, with low-risk patients having an 83.3% five-year overall survival and high-risk patients having a 25% five-year overall survival.
Michelle Williams, Assistant Professor at George Mason University, received $9,999 to host a lung cancer screening webinar series targeting healthcare providers in Mississippi. The goal is to decrease lung cancer incidence and mortality rates through increased screenings and smoking cessation.
A new study by Vanderbilt University researchers has cast doubt on the impact of a proposed ban on menthol-flavored tobacco cigarettes. The study found no statistically significant difference in quit rates between menthol and non-menthol smokers, despite earlier reports that menthols were harder to quit. The study's authors suggest cau...
A study in eLife found that fine air pollution particles can increase the risk of lung cancer by altering lung tissue structure and reducing immune cell infiltration. The researchers identified peroxidasin as a key enzyme responsible for this effect, which could lead to new approaches for preventing or treating lung disease.
A retrospective study found that higher coronary artery calcium score, higher pulmonary artery-to-aorta ratio, and lower thoracic skeletal muscle index independently predicted worse overall survival. The PA-to-aorta ratio was the most important predictor of overall survival.
Researchers at Purdue University discovered that some lung cancer patients become resistant to common therapeutics due to epigenetic regulation of the KMT5C gene. This understanding lays the groundwork for future therapeutics and provides insight into the biology and progression of cancers.